New Haven, CT – Dr. Giulia Biancon, an esteemed Associate Research Scientist at Yale University, has been bestowed with the prestigious 2024 Eclipse Award for Innovation in High Throughput Biology by the RNA Society and EclipseBio. The accolade recognizes her groundbreaking contributions to RNA biology, particularly in unraveling the complexities of RNA mechanisms implicated in myeloid malignancies.
Dr. Biancon's journey into scientific discovery began with her 2018 Ph.D. from the University of Milan, which she earned under the mentorship of Dr. Paolo Corradini. She is currently a member of Dr. Stephanie Halene's laboratory.
During her post-doctoral work, Dr. Biancon employed eCLIP technology to probe the binding patterns of mutant RNA splicing factor U2AF, a critical player implicated in various blood cancers.
Reflecting on her research, Dr. Biancon explained, "In the Halene Lab, we employ high-throughput methodologies to dissect the pathogenic RNA mechanisms underpinning splicing factor mutations in myeloid malignancies. Our findings underscore the profound impact of U2AF1 mutations on RNA binding dynamics, precipitating extensive alterations in the cellular transcriptome and subcellular compartmentalization" (Biancon G. et al. Mol Cell. 2022).
For Dr. Biancon, the Eclipse Award symbolizes a testament to her scientific achievements and a catalyst for continued advancement in RNA biology, particularly in cancer research.
In addition to her groundbreaking research, Dr. Biancon is a Yale Center for RNA Science and Medicine Coordinator. Her receipt of the 2024 Eclipse Award underscores her unwavering dedication to scientific inquiry. It serves as a beacon of inspiration for aspiring researchers striving to push the boundaries of knowledge in pursuit of transformative discoveries.
Dr. Giulia Biancon, an Associate Research Scientist at Yale University, has been honored with the 2024 Eclipse Award for Innovation in High Throughput Biology by the RNA Society and EclipseBio for her contributions to RNA biology, particularly in myeloid malignancies.